Subscribe
Subscribe
百济神州
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
BeiGene's New Drug Zebutinib Approved for Market in China
BeiGene Releases Updated Data from Phase 3 Head-to-Head Clinical Trial of Zebutinib
BeiGene and Chi-Med Enter into Clinical Collaboration for Solid Tumor and Cancer Drug Treatment
BeiGene to Launch More Innovative Products after Covid-19
BeiGene saw its stock price rose more than 3% and Hillhouse continued to invest in it heavily.
Annual Results Announcement for the Year Ended December 31, 2019
Announcement: Click hereBeigene were suspended imports in the sales volume of the purchase of goods, and the market is afraid of being carved up
Behind the 116% increase in revenue for BeiGene: the "breakup" with Xinji and the approval of blockbuster drugs
BeiGene (06160.HK) established a scientific advisory committee and a business advisory committee
BeiGene joined pd-1 price war, and the price war upgraded
Saying from the clinical results of BeiGene: the dilemma of Chinese pharmaceutical enterprises' development
Analysis of BeiGene‘s r & d pipeline
BeiGene-B (6160.HK) : The enterprise whcih is the second of the IPO series of overseas innovative pharmaceutical enterprises, a leading innovative pharmaceutical research and development enterprise with roots in China and has a global layout
BeiGene-B (6160.HK) : in-depth analysis of IPO
EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.
We strive to make technology inclusive, accessible and transparent.
Join over 70,000 of your peers
Beijing
9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
Shanghai
1027 Chang Ning Rd, 2206 Zhaofeng Plaza, Changning Dc, Shanghai 200042, China
New York
800 Third Ave, 28F, New York, NY 10022, USA
Cooperation strategy
Products & prices
Customers & evaluation
